Can you explain the purpose of this exercise. Does this "poll" suggest" all these ID's believe a buyout is forthcoming? While a BO would allow an easy exit for many on this board, I have come to the realization this may be wishful thinking. There is growing speculation within this industry that the thirst for CV assets has been significantly reduced in the last 36 months. The hefty premiums will be in oncology, gene therapy and orphan drugs.
The window has probably closed on Thero even with Europe, Covid and NASH on the table. However, our best hope probably resides with AZN. The buyout of The Medicines Group last November for roughly $9B probably puts the ceiling for AMRN in the same range. Three to five times peak sales of $3B WW would put the company at the magic $9B or $21 - $22 per share tops. Remember, with Thero's constant dilution, convertibles and outstanding options, there's now roughly 417M total shares outstanding. Like Yee said, if it doesn't happen by H1 2021, it will be a long slog for this company.